Scott J. Rodig

77.0k citations

347 papers · 33.8k indexed · 23 hit papers · h-index 85

Impact in

Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
Immunology top 0.05%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses

Papers in

Oncology 188
- Cancer Immunotherapy and Biomarkers 91
- CAR-T cell therapy research 42
Pathology and Forensic Medicine 105
- Lymphoma Diagnosis and Treatment 91

Co-authors: Margaret A. Shipp Bjoern Chapuy Gordon J. Freeman Philippe Armand Robert D. Schreiber Donna Neuberg Pasi A. Jänne Lucian R. Chirieac
Journals: Blood (54 papers)Journal of Clinical Oncology (38 papers)Cold Spring Harbor Protocols (18 papers)Clinical Cancer Research (16 papers)Cancer Immunology Research (13 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Scott J. Rodig

325 papers receiving 33.3k citations

Hit Papers

15 papers align trajectories log scale

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma 2018 · 408 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Science Translational Medicine
2017 Immunity
2017 Blood
2016 Genome biology
2016 Oncotarget
2016 Journal of Clinical Oncology
2015 Science Translational Medicine
2015 JAMA Oncology
2014 New England Journal of Medicine
2013 Cancer Cell
2013 Clinical Cancer Research
2012 New England Journal of Medicine
2012 Clinical Cancer Research
2012 Blood
2011 Cell stem cell
2010 New England Journal of Medicine
2010 Blood
2009 Journal of Clinical Oncology
2009 Clinical Cancer Research
2007 Nature
2007 Proceedings of the National Academy of Sciences
1998 Cell
1996 Cell

Peers

Countries citing papers authored by Scott J. Rodig

Since Specialization

Citations

This map shows the geographic impact of Scott J. Rodig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott J. Rodig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott J. Rodig more than expected).

Fields of papers citing papers by Scott J. Rodig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott J. Rodig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott J. Rodig. The network helps show where Scott J. Rodig may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Scott J. Rodig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Scott J. Rodig Line = papers co-authored together Scott J. Rodig links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging Blood Advances ·Kyle Wright, Jason L. Weirather, Sizun Jiang, Katrina Kao, Luis Jorge Copete Villamizar, Anita Giobbie‐Hurder, Margaret A. Shipp, Scott J. Rodig	2023	19
2	Targeting KDM2A Enhances T-cell Infiltration in NSD1-Deficient Head and Neck Squamous Cell Carcinoma Cancer Research ·J. Mill Frodsham, June Ho Shin, Zhuoqing Fang, Kevin Brennan, 義勝代田, Kathleen L. Pfaff, 富永保人, Scott J. Rodig, Olivier Gevaert, Or Gozani, Ravindra Uppaluri, John B. Sunwoo	2023	10
3	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer Cancer Immunology Research ·Carino Gurjao, David Liu, Matan Hofree, Saud H. AlDubayan, Isaac Wakiro, Mei-Ju Su, Kristen D. Felt, Evisa Gjini, Lauren K. Brais, Asaf Rotem, Michael H. Rosenthal, Orit Rozenblatt–Rosen, Scott J. Rodig, Kimmie Ng, Eliezer M. Van Allen, Steven M. Corsello, Shuji Ogino, Aviv Regev, Jonathan A. Nowak, Marios Giannakis	2019	60
4	Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment Blood ·Fathima Zumla Cader, Ron C.J. Schackmann, Xihao Hu, Kirsty Wienand, Robert Redd, Bjoern Chapuy, Jing Ouyang, Nicole Paul, Evisa Gjini, Mikel Lipschitz, Philippe Armand, David Wu, Jonathan R. Fromm, Donna Neuberg, X. Shirley Liu, Scott J. Rodig, Margaret A. Shipp	2018	111
5	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade Cancer Immunology Research ·Jun Zhou, Kathleen M. Mahoney, Anita Giobbie‐Hurder, Fengmin Zhao, Charles Lee, Xiaoyun Liao, Scott J. Rodig, Jingjing Li, Xinqi Wu, Lisa H. Butterfield, Matthias Piesche, Michael P. Manos, Lauren M. Eastman, Glenn Dranoff, Gordon J. Freeman, F. Stephen Hodi	2017	284
6	Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes Cancer Immunology Research ·Xinqi Wu, Jingjing Li, 茂樹本田, Xiaoyun Liao, Jing Ouyang, Anita Giobbie‐Hurder, Donald P. Lawrence, David F. McDermott, Gëorge F. Murphy, Jun Zhou, Matthias Piesche, Glenn Dranoff, Scott J. Rodig, Margaret A. Shipp, F. Stephen Hodi	2017	58
7	Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Cancer Immunology Research ·Margaretha G.M. Roemer, Ranjana H. Advani, Robert Redd, Geraldine S. Pinkus, Yasodha Natkunam, Azra H. Ligon, Courtney Connelly, Christine J. Pak, Christopher D. Carey, Sarah E. Daadi, Bjoern Chapuy, Daphne de Jong, Richard T. Hoppe, Donna Neuberg, Margaret A. Shipp, Scott J. Rodig	2016	139
8	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy Cancer Immunology Research ·Xinqi Wu, Anita Giobbie‐Hurder, Xiaoyun Liao, Courtney Connelly, 茂樹本田, Jingjing Li, Michael P. Manos, Donald P. Lawrence, David F. McDermott, Mariano Severgnini, Jun Zhou, Evisa Gjini, Ana Lako, Mikel Lipschitz, Christine J. Pak, Sara Abdelrahman, Scott J. Rodig, F. Stephen Hodi	2016	123
9	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma Cancer Immunology Research ·Sarah Derks, Katie S. Nason, Xiaoyun Liao, Matthew D. Stachler, Kevin X. Liu, Jie Bin Liu, Ewa Sicińska, Michael S. Goldberg, Gordon J. Freeman, Scott J. Rodig, Jon M. Davison, Adam J. Bass	2015	114
10	PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies Clinical Cancer Research ·Benjamin J. Chen, Bjoern Chapuy, Jing Ouyang, Heather H. Sun, Margaretha G.M. Roemer, Mina L. Xu, Hongbo Yu, Christopher D.�M. Fletcher, Gordon J. Freeman, Margaret A. Shipp, Scott J. Rodig Hit paper breakdown →	2013	657
11	Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas Proceedings of the National Academy of Sciences ·Monica Gostissa, Carlton J. Spotswood, V. V. Bryuzgin, Jeffery L. Kutok, Scott J. Rodig, Herbert C. Morse, Craig H. Bassing, Frederick W. Alt	2013	25
12	Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma Clinical Cancer Research ·Agata M. Bogusz, Richard H. G. Baxter, Treeve Currie, Papiya Sinha, Aliyah R. Sohani, Jeffery L. Kutok, Scott J. Rodig	2012	34
13	Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation Clinical Cancer Research ·Bryan M. Burt, Andrew Bader, Rasel, Scott J. Rodig, Raphael Bueno, David J. Sugarbaker	2012	32
14	Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy Clinical Cancer Research ·Michael R. Green, Scott J. Rodig, Przemysław Juszczyński, Jing Ouyang, Papiya Sinha, Evan A. O’Donnell, Donna Neuberg, Margaret A. Shipp Hit paper breakdown →	2012	551
15	A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease Cancer Research ·Diego J. Laderach, Lucas D. Gentilini, 刘柔嘉, M R Hadian Jazi, Gleice Reinert, Diego O. Croci, Nader Al Nakouzi, Paula Sacca, Gabriel Casas, Osvaldo Mazza, Margaret A. Shipp, Elba S. Vázquez, Anne Chauchereau, Jeffery L. Kutok, Scott J. Rodig, María T. Elola, Daniel Compagno, Gabriel A. Rabinovich	2012	138
16	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer Clinical Cancer Research ·Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julián Carretero, Yuchen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok‐Kin Wong, Geoffrey I. Shapiro	2012	131
17	Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program Proceedings of the National Academy of Sciences ·Michael R. Green, Stefano Monti, Riccardo Dalla‐Favera, Laura Pasqualucci, Nicole C. Walsh, Marc Schmidt‐Supprian, Jeffery L. Kutok, Scott J. Rodig, Donna Neuberg, Klaus Rajewsky, Todd R. Golub, Frederick W. Alt, Margaret A. Shipp, John Manis	2011	42
18	MLL -Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1 Clinical Cancer Research ·Przemysław Juszczyński, Scott J. Rodig, Jing Ouyang, Evan A. O’Donnell, Kunihiko Takeyama, Wojciech Młynarski, Flavio Quessada, Tomasz Szczepański, Lu Taian, Andrei V. Krivtsov, Joerg Faber, Amit Sinha, Gabriel A. Rabinovich, Scott A. Armstrong, Jeffery L. Kutok, Margaret A. Shipp	2010	28
19	Collagen XXIII: A Potential Biomarker for the Detection of Primary and Recurrent Non–Small Cell Lung Cancer Cancer Epidemiology Biomarkers & Prevention ·Susana Isaza Villegas, Jacqueline Banyard, Luisa M. Solis, Ignacio I. Wistuba, Justine A. Barletta, Leena Gandhi, Henry A. Feldman, Scott J. Rodig, Lucian R. Chirieac, Bruce R. Zetter	2010	29
20	Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population Clinical Cancer Research ·Scott J. Rodig, Mari Mino–Kenudson, Sanja Đačić, Beow Y. Yeap, Alice T. Shaw, Justine A. Barletta, Hannah Stubbs, Fitria Musannadah, Neal I. Lindeman, Eugene J. Mark, Pasi A. Jänne, Thomas J. Lynch, Bruce E. Johnson, A. John Iafrate, Lucian R. Chirieac Hit paper breakdown →	2009	526

About Scott J. Rodig

Scott J. Rodig is a scholar working on Oncology, Pathology and Forensic Medicine, Genetics, Immunology and Hematology, having authored 347 papers that have together received 33.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (91 papers), Lymphoma Diagnosis and Treatment (91 papers), CAR-T cell therapy research (42 papers), Immune Cell Function and Interaction (37 papers), Immunotherapy and Immune Responses (37 papers), Chronic Lymphocytic Leukemia Research (32 papers), Cancer Genomics and Diagnostics (27 papers) and Lung Cancer Treatments and Mutations (25 papers). The work is most often cited by research in Oncology (18.7k citations), Immunology (10.9k citations), Pathology and Forensic Medicine (8.2k citations), Genetics (3.9k citations) and Cancer Research (4.4k citations). Scott J. Rodig has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Margaret A. Shipp, Bjoern Chapuy, Gordon J. Freeman, Philippe Armand, Robert D. Schreiber, Donna Neuberg, Pasi A. Jänne, Lucian R. Chirieac, Jeffery L. Kutok and Heather H. Sun. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cold Spring Harbor Protocols, Clinical Cancer Research and Cancer Immunology Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact